CytoDyn Inc. , a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with ... (more)
http://ift.tt/MwyoA1
http://ift.tt/MwyoA1
No comments:
Post a Comment